Details of the Drug Reposition

General Information of This Drug (ID: DMX2P5G)

Drug Name
APX005M   DMX2P5G
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Brain cancer DISBKFB7 2A00 Phase 1 [2]
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Investigative [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04337931) A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).